EMEA-001032-PIP02-17

Key facts

Invented name
Opsumit
Active substance
Macitentan
Therapeutic area
Cardiovascular diseases
Decision number
P/0215/2017
PIP number
EMEA-001032-PIP02-17
Pharmaceutical form(s)
  • Dispersible tablet
  • Film-coated tablet
Condition(s) / indication(s)
Treatment of chronic thromboembolic pulmonary hypertension (CTEPH)
Route(s) of administration
Oral use
Contact for public enquiries
Actelion Registration Ltd.

Tel.+41 61 565 65 65
E-mail:clinical-trials-disclosure@its.jnj.com

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating
Average
1 rating